1. Prognostic factors for thyroid-stimulating immunoglobulin normalization in moderate-to-severe Graves’ orbitopathy: a 36-month longitudinal study
- Author
-
Jungyul Park, Yubin Son, Jinmi Kim, Sangsoo Kim, and Hee-young Choi
- Subjects
Graves’ orbitopathy ,Thyroid-stimulating immunoglobulin ,Thyroid-stimulating hormone receptor antibody ,Longitudinal study ,Success rate ,Ophthalmology ,RE1-994 - Abstract
Abstract Purpose The primary objective of this study was to identify predictive factors linked to the normalization of thyroid-stimulating immunoglobulin (TSI) levels in patients diagnosed with active, moderate-to-severe Graves’ orbitopathy (GO). The study also tracked the longitudinal changes in TSI levels over a 36-month period following treatment. Methods The study population consisted of individuals who were recently diagnosed with active, moderate-to-severe GO and received a 12-week course of intravenous methylprednisolone (IVMP) treatment. A subgroup of patients who did not respond to the initial treatment received an additional 20 Gy of radiation therapy (RTx). TSI levels were monitored at the time of diagnosis, after treatment, and subsequently every 6 months for 36 months. Normalization was defined as a TSI level below 140%. Patients were divdied into two groups with success and failure group depending on whether TSI became normal or not. Results Out of 83 patients, 36 (43.4%) achieved normalized TSI levels within two years post-IVMP treatment. Lower initial TSI levels (
- Published
- 2024
- Full Text
- View/download PDF